S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91

Allogene Therapeutics Stock Forecast, Price & News

+0.88 (+4.83%)
(As of 12/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
747,508 shs
Average Volume
1.25 million shs
Market Capitalization
$2.72 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Allogene Therapeutics logo

About Allogene Therapeutics

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.


Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Down to $18.67
November 29, 2021 |  americanbankingnews.com
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 3.1%
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$7.70 per share


Net Income
$-250.22 million
Pretax Margin




Free Float
Market Cap
$2.72 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.59 out of 5 stars

Medical Sector

84th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

8th out of 202 stocks

Analyst Opinion: 4.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

Is Allogene Therapeutics a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics
or view top-rated stocks.

How has Allogene Therapeutics' stock been impacted by Coronavirus?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLO shares have decreased by 23.8% and is now trading at $19.09.
View which stocks have been most impacted by COVID-19

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,670,000 shares, an increase of 19.6% from the October 31st total of 4,740,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 8.5% of the shares of the stock are sold short.
View Allogene Therapeutics' Short Interest

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Allogene Therapeutics

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Thursday, November, 4th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.01. The company had revenue of $0.05 million for the quarter. During the same quarter in the prior year, the business earned ($0.52) earnings per share.
View Allogene Therapeutics' earnings history

What price target have analysts set for ALLO?

16 brokers have issued 12-month price objectives for Allogene Therapeutics' shares. Their forecasts range from $18.00 to $53.00. On average, they expect Allogene Therapeutics' stock price to reach $36.23 in the next year. This suggests a possible upside of 89.8% from the stock's current price.
View analysts' price targets for Allogene Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:
  • David D. Chang, President, Chief Executive Officer & Director
  • Eric Schmidt, Chief Financial Officer
  • Barbra Sasu, Chief Scientific Officer
  • Alison Moore, Chief Technical Officer
  • Rafael G. Amado, Chief Medical Officer, EVP-Research & Development (LinkedIn Profile)

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.11%), Primecap Management Co. CA (2.53%), Alliancebernstein L.P. (2.26%), Casdin Capital LLC (1.47%), Goldman Sachs Group Inc. (1.39%) and Geode Capital Management LLC (0.88%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics

Which major investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citigroup Inc., Morgan Stanley, Schonfeld Strategic Advisors LLC, Barclays PLC, Victory Capital Management Inc., Caption Management LLC, and Deutsche Bank AG. Company insiders that have sold Allogene Therapeutics company stock in the last year include Eric Thomas Schmidt, Owen N Witte, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics
or view top insider-selling stocks.

Which major investors are buying Allogene Therapeutics stock?

ALLO stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Dimensional Fund Advisors LP, Nordea Investment Management AB, Goldman Sachs Group Inc., BlackRock Inc., Pier Capital LLC, Lombard Odier Asset Management Switzerland SA, and UBS Group AG.
View insider buying and selling activity for Allogene Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $19.09.

How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of $2.72 billion. The company earns $-250.22 million in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 265 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

Where are Allogene Therapeutics' headquarters?

Allogene Therapeutics is headquartered at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 457-2700 or via email at [email protected].

This page was last updated on 12/3/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.